Kymera Therapeutics shares are down about 3% as the market continues to price in a key partnership reset: Sanofi’s decision to stop advancing the IRAK4 degrader KT-474 and prioritize the next-generation KT-485 instead. The shift has led to incremental analyst model and price-target adjustments that emphasize timing risk around IRAK4-related milestones and push investor focus back toward Kymera’s wholly owned pipeline programs.

The Sanofi collaboration had been a major external validation point for Kymera’s IRAK4 platform, and KT-474’s discontinuation reduces visibility on nearer-term Phase 2 data and related milestone cadence. While KT-485 is positioned as a next-generation approach, its clinical start timing extends the timeline for value inflection and can create a valuation air pocket for investors who were positioned for quicker IRAK4 readouts.

Separate from pipeline headlines, recent Form 4 activity has shown notable insider selling at prices in the mid-$80s, which can amplify downside on weaker tape days even when sales are part of pre-arranged plans. With the stock up substantially over the past year, profit-taking and liquidity-driven selling can have an outsized impact on day-to-day moves when there is no new bullish clinical catalyst.